Teva hands over $450M to resolve kickback lawsuits involving MS drug Copaxone and generics

A little over four years after being sued by the United States, Teva is putting longstanding allegations that it paid kickbacks on a popular multiple sclerosis drug to bed.

Teva Pharmaceuticals USA and Teva Neuroscience have agreed to pay a combined $450 million to resolve claims that the company violated the country’s Anti-Kickback Statute (AKS) and the False Claims Act (FCA), the U.S. Department of Justice said Thursday.